All we can say is that this rapidly emerging company and Genomics Research leader, who has direct Federal past performance in support of NIH and VA genomic efforts, must have a compelling story and mission as they somehow managed to persuade industry veteran Theresa Holder to take on a more dedicated role.
Velsera’s vision is to be the discovery, evidence generation, and clinical delivery platform for precision medicine. We help doctors and drug hunters make better decisions about providing the right therapy to the right patients at the right time. We have spent the last 10+ years’ developing industry leading clinical software, knowledge and perspectives on genetic disease – including oncology, rare and hereditary diseases.
Velsera was formed in January 2022 through the merger of three leading precision medicine companies – Perian Dx in the clinical diagnostics space, Seven Bridges in the life science analytics domain and UgenTec in the clinical laboratory automation industry. Today, Velsera employs 600 people across US, Europe and Asia, including over 150 employees with MD/PhD across their own in-house scientific, bioinformatic and clinical expert teams.
Not Yet a Premium Partner/Sponsor? Learn more about the OS AI Premium Corporate and Individual Plans here. Plans start at $250 annually.